News
NRSN
1.040
+4.00%
0.040
NeuroSense Therapeutics Calls March 10, 2026 Special Meeting to Approve Share Capital Increase
TipRanks · 23h ago
NeuroSense Therapeutics Proposes Increase in Registered Share Capital at Upcoming Shareholder Meeting
Reuters · 23h ago
NeuroSense Wins Australian Patent to Extend PrimeC IP Protection Through 2042
TipRanks · 5d ago
NeuroSense granted Australian patent covering PrimeC composition
TipRanks · 5d ago
NeuroSense Therapeutics Granted Australia Patent For Its PrimeC
Benzinga · 5d ago
NeuroSense erhält australisches Patent für PrimeC-Kombinationstherapie
Reuters · 5d ago
NeuroSense Therapeutics Secures Australian Patent for PrimeC, Expanding Global IP Protection Through 2042
Reuters · 5d ago
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition
PR Newswire · 5d ago
Weekly Report: what happened at NRSN last week (0202-0206)?
Weekly Report · 5d ago
Weekly Report: what happened at NRSN last week (0126-0130)?
Weekly Report · 02/02 09:55
NeuroSense files $150M mixed securities shelf
TipRanks · 01/29 22:30
Weekly Report: what happened at NRSN last week (0119-0123)?
Weekly Report · 01/26 09:55
NeuroSense Therapeutics Granted Parent From U.S. Patent And Trademark Office For Use Of PrimeC Combination In Alzheimer' Disease
Benzinga · 01/21 13:45
NeuroSense Therapeutics Granted U.S. Patent for Alzheimer's Disease Treatment, Extending Protection Through 2043
Reuters · 01/21 13:31
Weekly Report: what happened at NRSN last week (0112-0116)?
Weekly Report · 01/19 09:59
Weekly Report: what happened at NRSN last week (0105-0109)?
Weekly Report · 01/12 09:58
NeuroSense Therapeutics Appoints Alzheimer's Expert Steven Arnold to Scientific Advisory Board
Reuters · 01/08 13:45
NeuroSense Shareholders Approve Equity Grants to Directors and CEO to Preserve Cash
TipRanks · 01/06 22:47
Weekly Report: what happened at NRSN last week (1229-0102)?
Weekly Report · 01/05 09:54
Weekly Report: what happened at NRSN last week (1222-1226)?
Weekly Report · 12/29/2025 09:53
More
Webull provides a variety of real-time NRSN stock news. You can receive the latest news about Neurosense Therapeutics Ltd through multiple platforms. This information may help you make smarter investment decisions.
About NRSN
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease